HIM
KPTI icon

Hillsdale Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Hillsdale Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,280
Closed -$648K – 618
2020
Q2 		$648K Sell
2,280
-67
-3% -$19.8K 0.06% 275
2020
Q1 		$676K Buy
+2,347
New +$647K 0.08% 221

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Hillsdale Investment Management's KPTI Position: Q3 2020 in Review

Hillsdale Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 2,280 shares — an estimated $648K sold.

Hillsdale Investment Management first reported a position in KPTI in Q1 2020 and held it in 2 quarters. The position peaked at $676K in Q1 2020. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

  • Hillsdale Investment Management reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Hillsdale Investment Management sold 2,280 Karyopharm Therapeutics shares in Q3 2020, an estimated $648K.
  • Hillsdale Investment Management first reported a position in Karyopharm Therapeutics in Q1 2020 and held it in 2 quarters.
  • Hillsdale Investment Management's Karyopharm Therapeutics position peaked at $676K in Q1 2020.
  • 157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on Hillsdale Investment Management's 13F filing for Q3 2020, filed 13 Nov 2020.